Keresty Georgia 4

What Happened
Director Georgia Keresty received two equity awards from Intellia Therapeutics on June 9, 2026: 9,200 restricted stock units (RSUs) and a 13,300-share option grant. Both were recorded at an acquisition price of $0.00 on the Form 4; the RSUs represent a contingent right to receive one share per RSU, and the 13,300-share award is an option that vests according to the schedule below. These were grants/awards (not open-market purchases or sales).

Key Details

• Transaction date: June 9, 2026; Form 4 filed June 10, 2026 (filed promptly the next day).
• Transaction type/code: A = Award/Grant/Other acquisition.
• Awards: 9,200 RSUs (F1: each converts to one common share upon vesting); 13,300-share option (F2: vests in full on earlier of the first anniversary of the grant or the next annual meeting).
• Reported acquisition price: $0.00 for both awards (grant price; fair value not shown on Form 4).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes: F1 explains the RSUs are contingent rights to receive shares; F2 describes the option vesting timetable.
• No sale or exercise occurred — these are compensation awards, not a disposition or cash exercise.

Context: RSUs and option grants are routine forms of executive/director compensation and do not by themselves indicate an immediate buy/sell view. RSUs convert to shares only upon vesting; options here vest at the earlier of one year or the next annual meeting. Because these were grants (not purchases or sales), there was no cash paid by the insider at grant time.